Award Data

DESCRIPTION (provided by applicant): This STTR Phase I proposal describes the development of a modeling framework that combines a mesoscopic model for hydrodynamics with dissolution kinetic models in order to accurately describe the dissolution behavior of drugs. The complexities of the drug dissolution problem have led to the development of empirical methodologies being the widespread practice in ...

DESCRIPTION (provided by applicant): Phoenicia Biosciences, Inc. scientists have discovered a small family of low MW compounds (short-chain fatty acid derivatives (SCFADs) - designated Hemokines ) that stimulate proliferation of human hematopoietic progenitors, multi-lineage-hematopoietic cell lines, and have increased red blood cell counts in animal models, with oral administration. Recently, se ...

DESCRIPTION (provided by applicant): The objective of this project is to develop a system to optically record fluorescence signals from heart tissues in vivo. Fluorescent dyes have been used to record biological processes from the heart for more than a decade. Specifically, staining the heart with voltage-sensitive dyes -which emit fluorescence that varies with the membrane potential-and using hig ...

DESCRIPTION (provided by applicant): Tobacco use remains the single most preventable cause of premature deaths and cancer.1 Building on more than a decade of clinical and research experience in treating tobacco-dependence, we propose to address this problem with a new academic-small computer game business partnership that will develop a novel e-health tobacco cessation and relapse prevention produ ...

DESCRIPTION (provided by applicant): The proposed project is designed to fill an extremely important yet unmet need by developing an alternative training mechanism that has the potential for reaching all personnel responsible for risk management and quality improvement in programs that provide services to persons with mental retardation/developmental disabilities (MRDD) and the public agency staff ...

DESCRIPTION (provided by applicant): A major cause of morbidity and mortality in cardiovascular surgery is excessive bleeding post- operatively, which is commonly managed by pharmacologically modifying clot degradation (fibrinolysis), through inhibition of plasmin activity (PLact). However, the only FDA approved and most commonly used inhibitor of PLact in cardiovascular surgery, while eff ...